干扰素 λ 3（白细胞介素 28B）多态性对慢性乙型肝炎病毒感染患者治疗后持续病毒学应答的影响。
Effects of polymorphisms in interferon λ 3 (interleukin 28B) on sustained virologic response to therapy in patients with chronic hepatitis D virus infection.
机构信息
Department of Gastroenterohepatology, Istanbul Faculty of Medicine, Istanbul University, Capa, Istanbul, Turkey; Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Capa, Istanbul, Turkey.
Department of Gastroenterohepatology, Istanbul Faculty of Medicine, Istanbul University, Capa, Istanbul, Turkey.
出版信息
Clin Gastroenterol Hepatol. 2014 Oct;12(10):1753-8. doi: 10.1016/j.cgh.2014.01.043. Epub 2014 Feb 26.
BACKGROUND & AIMS: We investigated the association between interferon λ 3 (IFNL3) genotype (also known as interleukin 28B) and response to IFNα therapy in patients with chronic hepatitis D virus (HDV) infection.
METHODS
We studied IFNL3 genotypes of 32 patients (19 men; median age, 42.5 y) with chronic HDV infection. Nineteen patients (59%) were treated with pegylated IFNα and 13 patients (41%) were treated with standard IFNα, for at least 12 months. Levels of HDV RNA were measured before the initiation of treatment and every 6 months thereafter; patients were followed up for a median time of 16 months (range, 6-164 mo) after treatment ended. We used real-time polymerase chain reaction to classify the IFNL3 polymorphism rs12979860 as CC, CT, or TT, and rs8099917 as TT, GT, or GG. A virologic response was defined as undetectable HDV RNA in serum, and a sustained virologic response (SVR) was defined as undetectable HDV RNA after cessation of treatment until the end of the follow-up period. We evaluated the association between IFNL3 polymorphism and treatment response using univariate and multivariate analyses.
RESULTS
After treatment, a response was achieved in 16 patients (50%) and an SVR was achieved in 9 (28%). The percentages of patients with CC, CT, and TT at rs12979860 were 47%, 47%, and 6%, respectively; the percentages of patients with TT, GT, and GG at rs8099917 were 69%, 28%, and 3%, respectively. Rates of SVR were 27%, 27%, and 50% in patients with CC, CT, TT at rs12979860 (P = .78 for CC vs CT vs TT) and 36%, 11%, and 0% in patients with TT, GT, and GG at rs8099917 (P = .30 for TT vs GT vs GG).
CONCLUSIONS
The IFNL3 polymorphisms rs12979860 and rs8099917 do not significantly affect responses of patients with chronic HDV infection to treatment with IFNα.
背景与目的
我们研究了干扰素 λ 3（IFNL3）基因型（亦称白细胞介素 28B）与慢性丁型肝炎病毒（HDV）感染患者对 IFNα 治疗应答的相关性。
方法
我们研究了 32 例慢性 HDV 感染患者（19 例男性；中位年龄 42.5 岁）的 IFNL3 基因型。19 例（59%）患者接受聚乙二醇干扰素α治疗，13 例（41%）患者接受标准干扰素α治疗，疗程至少 12 个月。治疗开始前和此后每 6 个月测量一次 HDV RNA 水平；治疗结束后中位随访时间为 16 个月（范围 6-164 个月）。我们采用实时聚合酶链反应将 IFNL3 多态性 rs12979860 分为 CC、CT 或 TT，rs8099917 分为 TT、GT 或 GG。病毒学应答定义为血清中不可检测到 HDV RNA，持续病毒学应答（SVR）定义为治疗停止后直至随访结束时仍不可检测到 HDV RNA。我们采用单变量和多变量分析评估 IFNL3 多态性与治疗应答的相关性。
结果
治疗后，16 例（50%）患者获得应答，9 例（28%）患者获得 SVR。rs12979860 处 CC、CT 和 TT 的患者百分比分别为 47%、47%和 6%；rs8099917 处 TT、GT 和 GG 的患者百分比分别为 69%、28%和 3%。rs12979860 处 CC、CT 和 TT 的 SVR 率分别为 27%、27%和 50%（CC 与 CT 与 TT 相比，P =.78），rs8099917 处 TT、GT 和 GG 的 SVR 率分别为 36%、11%和 0%（TT 与 GT 与 GG 相比，P =.30）。
结论
IFNL3 多态性 rs12979860 和 rs8099917 对慢性 HDV 感染患者对 IFNα 治疗的应答无显著影响。
Zotero 插件